The U.S. National Cancer Institute (NCI) has awarded funding of more than $95 million to NRG Oncology to continue its work as a lead protocol organization (LPO) program.
The money will cover the next six years for NRG Oncology to advance its participation in the NCI's National Clinical Trials Network (NCTN) to conduct novel clinical and translational research. NRG Oncology plans to develop a strategy to improve support, guidance, and education pathways for young investigators and raise awareness of clinical cancer research, among other goals.
"We will continue to leverage NRG Oncology's network of physicians and nurses, statisticians, patient advocates, and other professionals to conduct meaningful research and through this research improve the lives of those affected by cancer," said Dr. Robert Mannel, group chair for NRG Oncology and director of the Stephenson Cancer Center at the University of Oklahoma.
